These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7544169)

  • 21. Effective treatment of advanced breast cancer with vinorelbine, 5-fluorouracil and l-leucovorin plus human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Lang F; Krauss G; Hejna M; Raderer M; Weinländer G; Depisch D; Scheithauer W
    Br J Cancer; 1998 Sep; 78(5):673-8. PubMed ID: 9744509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-finding study of paclitaxel and cyclophosphamide in advanced breast cancer.
    Pagani O; Sessa C; Martinelli G; Cerny T; de Jong J; Goldhirsch A; Zimatore M; Cavalli F
    Ann Oncol; 1997 Jul; 8(7):655-61. PubMed ID: 9296218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ifosfamide given by continuous-intravenous infusion in association with vinorelbine in patients with anthracycline-resistant metastatic breast cancer: a phase I-II clinical trial.
    Campisi C; Fabi A; Papaldo P; Tomao S; Massidda B; Zappala A; Ionta MT; Cognetti F
    Ann Oncol; 1998 May; 9(5):565-7. PubMed ID: 9653499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/phase II trial of granulocyte colony-stimulating factor as bone marrow support in patients treated with vinorelbine (Navelbine): study design and goals.
    Havlin K
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):38-40; discussion 41-4. PubMed ID: 7537912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer.
    Gridelli C; De Placido S; Pepe R; Incoronato P; Airoma G; Rossi A; Palazzolo G; Bianco AR
    Eur J Cancer; 1993; 29A(12):1729-31. PubMed ID: 7691117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
    Sparano JA; Robert N; Silverman P; Lazarus H; Malik U; Venkatraj U; Sarta C
    J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
    Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
    J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
    Pérez-Gracia JL; Colomer R; Esteban E; Barceló R; Benavides M; Puertas J; Arcediano A; Tornamira MV; Valentín V; Muñoz A; Cortés-Funes H; Hornedo J
    Cancer; 2001 Nov; 92(10):2508-16. PubMed ID: 11745183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I study of Doxil and vinorelbine in patients with advanced malignancies.
    Laufman LR; Spiridonidis CH; Jones JJ; Rhodes V; Rossi K; Wallace K
    Cancer Invest; 2004; 22(3):344-52. PubMed ID: 15493354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicin-treated patients.
    Ellis GK; Gralow JR; Pierce HI; Williams MA; Livingston RB
    J Clin Oncol; 1999 May; 17(5):1407-12. PubMed ID: 10334525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Primary chemotherapy with epirubicin and vinorelbine in women with locally advanced breast cancer.
    Nisticò C; De Matteis A; Rossi E; Carnino F; Valenza R; Agostara B; Bria E; Farris A; Cremonesi M; D'Ottavio AM; Vaccaro A; Garufi C; Giunta S; Botti C; Perrone F; Terzoli E
    Anticancer Res; 2005; 25(2B):1343-8. PubMed ID: 15865089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
    De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
    Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor.
    Haider K; Kornek GV; Kwasny W; Weinländer G; Valencak J; Lang F; Püribauer F; Kovats E; Depisch D; Scheithauer W
    Breast Cancer Res Treat; 1999 Jun; 55(3):203-11. PubMed ID: 10517165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose intensification--a phase I study of ifosfamide with vinorelbine (Navelbine): rationale and study design in advanced non-small cell lung cancer.
    Drinkard LC; Hoffman PC; Samuels BL; Watson S; Bitran JD; Golomb HM; Vokes EE
    Semin Oncol; 1995 Apr; 22(2 Suppl 5):30-7; discussion 41-4. PubMed ID: 7537911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The multifractionated, twice-weekly dose schedule for a three-drug chemotherapy regimen: a phase I-II study of paclitaxel, cisplatin, and vinorelbine.
    Lokich JJ; Anderson N; Bern M; Coco F; Dow E
    Cancer; 1999 Jan; 85(2):499-503. PubMed ID: 10023721
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study.
    Frasci G; Comella P; Parziale A; Casaretti R; Daponte A; Gravina A; De Rosa L; Gallipoli A; Comella G
    Ann Oncol; 1997 Mar; 8(3):291-3. PubMed ID: 9137800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group.
    Colucci G; Giotta F; Gebbia V; Riccardi F; Pezzella G; Durini E; Caruso M; Romito S; Gebbia N
    Anticancer Drugs; 1997 Mar; 8(3):257-64. PubMed ID: 9095330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dense vinorelbine and paclitaxel with granulocyte colony-stimulating factor in metastatic breast cancer patients: anti-tumor activity and peripheral blood progenitor cell mobilization capability.
    Ballestrero A; Montemurro F; Gonella R; Capaldi A; Danova M; Friedman D; Puglisi M; Aglietta M; Patrone F
    Breast Cancer Res Treat; 2003 Dec; 82(3):185-90. PubMed ID: 14703065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.